(Information sent by the signatory company)
Transpara is implanted for clinical use by key opinion leaders in radiology and breast imaging
BALTIMORE, March 12, 2024 /PRNewswire/ — ScreenPoint Medical today announced that its industry-leading Transpara Breast AI is available to improve cancer detection in patients undergoing breast cancer screening at Johns Hopkins . Transpara assists radiologists with reading 2D and 3D mammography exams, providing a “second pair” of eyes to help detect cancers earlier and reduce recall rates.
The Johns Hopkins Kimmel Cancer Center was one of the first to be recognized by the National Cancer Institute as a “Center of Excellence.” Across Johns Hopkins, the breast imaging services team performs more than 77,000 breast imaging exams and 5,000 interventional procedures each year. The choice to use Transpara was made after a thorough analysis of the evidence, effectiveness and performance of the software in selected cases. Transpara, trusted by key opinion leaders in breast imaging around the world, was evaluated in a comprehensive competitive comparison by the Johns Hopkins Breast Imaging team.
ScreenPoint’s customer success team worked closely with Johns Hopkins clinical and IT teams to install Transpara Breast AI to support patient care across seven locations. Transpara was chosen to improve screening workflow, decision confidence and evaluation of breast cancer diagnosis.
“We are delighted that Johns Hopkins has trusted ScreenPoint Medical in its fight against cancer. Transpara is the most clinically validated breast AI on the market and has been shown to improve radiologists’ ability to detect breast cancer as early as possible. As part of The ScreenPoint Experience, Once a customer has chosen to use Transpara, we want to create those benefits in weeks, not months,” explained Nicki Bryan, vice president of sales at ScreenPoint Medical. “We are also very grateful to the professionals on the Johns Hopkins team who collaborated so effectively to ensure a smooth and seamless technical transition.”
With the addition of Johns Hopkins, Transpara’s growing utilization in the Northeast will now benefit radiologists and patients at more than 50 sites in five states (NY, NJ, PA, MD, VA) and the District of Columbia.
Transpara is FDA approved and European MDR approved for use with 2D and 3D mammograms from multiple manufacturers. Used by hundreds of leading centers in more than 30 countries. Transpara is designed to work simultaneously with radiologists. Research shows that up to 45% of interval cancers can be detected earlier using Transpara, while helping to reduce workload and optimize workflow.
About ScreenPoint Medical
ScreenPoint Medical translates cutting-edge machine learning research into technology accessible to radiologists to improve screening workflow, decision confidence, and breast cancer risk assessment. Transpara is trusted by radiologists around the world because it has been developed by experts in machine learning and image analysis and updated with feedback from users of world-renowned breast imagers. View all evidence at: https://screenpoint-medical.com/published-evidence/peer-reviewed-publications
Photo – https://mma.prnewswire.com/media/2360202…Logo – https://mma.prnewswire.com/media/1582198…
View original content: https://www.prnewswire.com/news-releases/screenpoint-medical-implanta-la-transpara-breast-ai-en-johns-hopkins-para-mejorar-la-deteccion-del-cancer-302086729.html
